经历过四年医药调整煎熬后,内地公募医药基金经理岁末年初以来逐渐扬眉吐气,尤其近期重仓创新药板块的基金脱颖而出,这也让医药主题基金苦尽甘来。还不仅是医药主题产品关注度陡增,近期披露结束的公募一季报显示全市场类基金纷纷加仓医药生物产业链相关标的,一时间医药生物板块仿佛一夜回到2019、2020年的盛景中。究竟应该如何看待这一轮医药股上涨?它是昙花一现还是代表着产业彻底走出了低谷呢?政策的保驾护航下,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.